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Abstract
 
The M protein of 
 
Streptococcus pyogenes
 
 is a major bacterial virulence factor that confers resistance
to phagocytosis. To analyze how M protein allows evasion of phagocytosis, we used the M22
protein, which has features typical of many M proteins and has two well-characterized regions
binding human plasma proteins: the hypervariable NH
 
2
 
-terminal region binds C4b-binding
protein (C4BP), which inhibits the classical pathway of complement activation; and an adjacent
semivariable region binds IgA-Fc. Characterization of chromosomal 
 
S. pyogenes
 
 mutants dem-
onstrated that each of the ligand-binding regions contributed to phagocytosis resistance, which
could be fully explained as cooperation between the two regions. Deposition of complement
on 
 
S. pyogenes
 
 occurred almost exclusively via the classical pathway, even under nonimmune
conditions, but was down-regulated by bacteria-bound C4BP, providing an explanation for
the ability of bound C4BP to inhibit phagocytosis. Different opsonizing antisera shared the
ability to block binding of both C4BP and IgA, suggesting that the two regions in M22 play
important roles also under immune conditions, as targets for protective antibodies. These data
indicate that M22 and similar M proteins confer resistance to phagocytosis through ability to
bind two components of the human immune system.
Key words: innate immunity • group A streptococcus • phagocytosis resistance •
complement • IgA
 
Introduction
 
A pathogenic microorganism infecting a nonimmune host
must evade attack from the innate immune system before
infection can be established (1). For extracellular pathogens,
such as many bacteria, it may be particularly important to
evade phagocytosis by neutrophils, which are rapidly recruited
to the site of an infection (2). Indeed, many bacterial
pathogens express surface structures that interfere with
phagocytosis by neutrophils (2–4). A classical example of
such an antiphagocytic surface molecule is the M protein of
 
Streptococcus pyogenes
 
 (group A streptococcus), which allows
this pathogen to grow rapidly in human blood (5). Here,
we analyze the mechanism by which M protein allows 
 
S.
pyogenes
 
 to evade phagocytosis.
 
S. pyogenes
 
 is a gram-positive bacterium causing a variety
of diseases, including acute pharyngitis, skin infections, a
toxic shock syndrome, and rheumatic fever (6). The surface
M protein of 
 
S. pyogenes
 
 plays a key role in conferring
phagocytosis resistance (5), but the hyaluronic acid capsule
expressed by many strains also makes an important contri-
bution (7). The M protein is a dimeric coiled coil with an
NH
 
2
 
-terminal hypervariable region (HVR) that exhibits
extensive sequence variability between strains, allowing
 
classification of clinical 
 
S. pyogenes
 
 isolates into 
 
 
 
120 different
M types (8).
Antibodies directed against the HVR block the antiphago-
cytic property of M protein, implying that the HVR plays
an important role in conferring phagocytosis resistance (5,
9, 10). However, the extreme sequence variability in the
HVR has made it difficult to explain how this region can
have the specific function to inhibit phagocytosis. To explain
this apparent paradox, it has been suggested that the HVR
causes repulsion of phagocytes by having a negative
charge, a mechanism that might allow extensive sequence
variability (5, 11). In agreement with this hypothesis, M
protein is known to inhibit binding of 
 
S. pyogenes
 
 to non-
activated phagocytes (12). However, evidence has accu-
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mulated that the HVR also has a specific ligand-binding
function. In particular, the HVRs of many M proteins spe-
cifically bind the human complement regulator C4b-bind-
ing protein (C4BP), a 
 
 
 
570-kD plasma protein that inhib-
its the classical pathway of complement activation by
accelerating the decay of the C3 convertase of this pathway
and by acting as a cofactor to factor I in the degradation of
C4b (13–17). Importantly, 
 
 
 
50% of clinical 
 
S. pyogenes
 
isolates bind C4BP, and all available evidence indicates that
this property is due to expression of an M protein in which
the HVR binds C4BP (13–15, 18).
In a previous paper, we showed that binding of C4BP to
the HVR can partially explain the ability of an M protein
to confer phagocytosis resistance (19), but the mechanism
by which the M protein confers full resistance to phagocy-
tosis remained unclear. Moreover, the contribution of bac-
teria-bound C4BP to phagocytosis resistance was puzzling,
because C4BP specifically down-regulates the classical
pathway of complement activation (16, 17), which is com-
monly believed not to be activated under nonimmune
conditions. The data reported here provide explanations
for both of these problems.
Our studies were focused on the M22 protein (19), which
has properties typical of many M proteins and is commonly
expressed by clinical isolates of 
 
S. pyogenes
 
 (20). In addition
to an HVR that binds C4BP, the M22 protein has an adja-
cent semivariable region that binds human IgA-Fc, another
common M protein ligand (21–24). Because the IgA-bind-
ing region varies in sequence between different M proteins
(23), we hypothesized that this region is a target for protec-
tive antibodies and contributes to phagocytosis resistance.
The studies described here show that the C4BP- and
IgA-binding regions of the M22 protein cooperate in con-
ferring phagocytosis resistance and can fully account for
the antiphagocytic property of M22. Moreover, bacteria-
bound C4BP down-regulated complement activation, that
occurred via the classical pathway even under nonimmune
conditions, providing an explanation for the ability of
bound C4BP to inhibit phagocytosis. Thus, a coherent pic-
ture is now emerging of the mechanisms, by which M22
and related M proteins confer phagocytosis resistance.
 
Materials and Methods
 
Bacterial Strains. S. pyogenes
 
 AL168 is an OF
 
 
 
 strain of sero-
type M22. Like other OF
 
 
 
 strains of 
 
S. pyogenes
 
, this strain has
three adjacent genes encoding members of the M protein family,
the 
 
mrp
 
, 
 
emm
 
, and 
 
enn
 
 genes (25). The strain referred to here as
M22 positive is strain AL168
 
mrp22
 
 
 
emm22
 
 
 
, which expresses the
M22 (Sir22) protein, but not the Mrp22 protein, which also con-
tributes to phagocytosis resistance (25). The isogenic strain re-
ferred to as M22 negative lacks expression of the M22 and Mrp22
proteins (25). The 
 
Escherichia coli
 
 XL-1 strain and the pUC19 vec-
tor were used for subcloning. 
 
S. pyogenes
 
 was grown without
shaking in Todd-Hewitt (TH) broth (Difco) or TH supple-
mented with 0.2% yeast extract in 5% CO
 
2
 
 at 37
 
 
 
C.
 
Mutations in the Chromosomal emm22 Gene That Specifically Block
the Ability of S. pyogenes to Bind IgA or C4BP.
 
A mutant (
 
 
 
14)
of strain AL168 lacking the ability to bind IgA was constructed by
the introduction of an in frame deletion in the 
 
emm22
 
 gene (26),
corresponding to 14 amino acid residues (67–80) in the IgA-
binding region (27). A 
 
 
 
900-nucleotide fragment from the
 
emm22
 
 gene, including the region to be deleted and 
 
 
 
430 nucle-
otides on either side, was PCR amplified from AL168 DNA, us-
ing forward and reverse primers with BamHI and EcoRI sites,
respectively. After ligation into pUC19, the construct was trans-
formed into 
 
E. coli
 
 XL-1, and transformants were screened by
PCR for the presence of the insert. One positive clone was veri-
fied by DNA sequencing. The deletion was introduced by a sec-
ond PCR using forward and reverse primers complementary to
regions downstream and upstream of the desired deletion, respec-
tively, thereby amplifying the entire construct, including the vec-
tor, except the sequence to be deleted. The PCR product was li-
gated with blunt ends and transformed into 
 
E. coli
 
 XL-1, and
transformants were screened by PCR for inserts with the desired
deletion and verified by DNA sequencing.
To introduce the 
 
 
 
14 mutation into the chromosome of 
 
S.
pyogenes
 
, the mutated 
 
emm22
 
 gene was transferred by PCR from
pUC19 to pJRS233, a shuttle vector that exhibits temperature-
sensitive replication in 
 
S. pyogenes
 
 (28). The derivative of
pJRS233 was electroporated into AL168
 
mrp22
 
 
 
emm22
 
 
 
, and the
desired recombinant was isolated essentially as described previ-
ously (25, 28). A clone of the desired type was identified, and the
sequence of the entire mutated chromosomal 
 
emm22
 
 gene, in-
cluding the promoter region, was verified by DNA sequencing.
A strain (
 
 
 
7) expressing an M22 variant with a seven-residue
deletion in the C4BP-binding region has been described previ-
ously (19). A strain carrying both of the 
 
 
 
7 and 
 
 
 
14 mutations
was constructed essentially as described for the 
 
 
 
14 strain, except
that the 
 
 
 
900-nucleotide fragment was PCR-amplified from
chromosomal DNA derived from the 
 
 
 
7 strain. The sequence of
the mutated chromosomal gene, including the promoter region,
was verified by DNA sequencing. This double mutant is referred
to as 
 
 
 
7
 
 
 
14. A revertant (rev.) strain, in which the wild-type
 
emm22
 
 gene was reintroduced into the 
 
 
 
7
 
 
 
14 mutant, was con-
structed as described previously (19).
 
Purified Proteins and Synthetic Peptides.
 
Human IgA was pur-
chased from Cappel Organon-Teknika. Purified human C4BP
was provided by B. Dahlbäck (Lund University, Lund, Sweden).
The IgG-Fc–binding reagents protein A and protein G were pur-
chased from Amersham Biosciences. The M22 (Sir22) protein
was purified as described previously (26). Synthetic 
 
 
 
50-residue
peptides derived from different M protein regions were prepared
with a COOH-terminal Cys residue, not present in the M pro-
tein, allowing dimerization and strongly enhancing ligand-bind-
ing (15, 29). The 53-residue peptide M22-N and the 50-residue
peptide Sap22 were derived from the C4BP- and IgA-binding re-
gions of M22, respectively (15, 27). The 54-residue C22 peptide
was derived from residues 131–182 in the conserved C-repeat re-
gion of M22, with addition of the sequence Tyr-Cys at the
COOH-terminal end; the Tyr residue was added to facilitate ra-
diolabeling. The 53-residue M5-N peptide includes the NH
 
2
 
-
terminal part of the processed form of the M5 protein (15). These
 
 
 
50-residue peptides were purchased from the Department of
Clinical Chemistry, Malmö General Hospital and were dimerized
as described previously (15). The 19-residue synthetic peptide
M22 (1–19), derived from the NH
 
2
 
-terminal sequence of the
processed form of the M22 protein, was conjugated to ovalbumin
via an added COOH-terminal Cys residue (Medprobe).
 
Antisera and mAbs.
 
Rabbit antisera to dimerized preparations
of the synthetic peptides M22-N, Sap22, and C22 were prepared
as described previously (15, 19). Rat antisera against a syntheticT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
Carlsson et al.
 
1059
 
peptide, M22 (181–201), derived from the conserved C-repeat
region of the M22/M4 proteins, were prepared as described pre-
viously (23). Mouse antiserum against the synthetic peptide M22
(1–19) was raised by immunizing NMRI mice twice with 20 
 
 
 
g
OVA–peptide conjugate in Freund’s adjuvants. Mouse mAbs
against human C3d, C4c, and C4d were from Quidel Corp. The
mouse anti-C4BP mAb67 (30) was a gift from B. Dahlbäck.
Mouse IgG1 (Quidel Corp.) was used as a control because all
monoclonal antibodies used were of this isotype. FITC-conju-
gated goat F(ab
 
 
 
)
 
2
 
 anti–mouse IgG (DakoCytomation) was used
for detection. Rabbit antisera against the overlapping M22-N and
Sap22 peptides were made specific for the homologous peptide
by passing 2-ml samples repeatedly through 1-ml HiTrap col-
umns (Amersham Biosciences) containing 5 mg of immobilized
heterologous peptide.
 
Affinity Chromatography.
 
5 mg of dimerized preparations of
the M22-N, Sap22, and M5-N peptides were immobilized in
1-ml HiTrap columns, as described previously (15). 1 ml of human
plasma, prepared with hirudin (final concentration, 140 U/ml;
Calbiochem) as anticoagulant, was diluted 1:5 in PBS and applied
to each column, which was washed with 10 ml PBS. The col-
umns were eluted as described previously (15, 29) and eluates
were dialyzed against PBS.
 
Binding Assays.
 
Binding of 
 
125
 
I-labeled human C4BP and IgA
to whole streptococci was analyzed as described previously (25).
Binding is expressed as a percentage of that observed with the
positive control, which was 
 
 
 
60% for both C4BP and IgA.
Binding of rat antibodies to whole bacteria was detected with ra-
diolabeled protein A (31). Binding (
 
 
 
3%) in control tubes with
preimmune rat serum was deduced.
The reactivity of different rabbit antisera with the M22 protein
and with synthetic peptides was analyzed in microtiter wells
coated with 1 
 
 
 
g/ml of pure M22 or 2 
 
 
 
g/ml of peptide, as indi-
cated, and detected with radiolabeled protein G, essentially as de-
scribed previously (15, 19).
The ability of antisera to inhibit the interaction between M22
and radiolabeled C4BP or IgA was analyzed in microtiter wells
coated with pure M22 protein, as described previously (19). Inhi-
bition is expressed as a percentage of the binding observed in the
absence of antiserum, which was 
 
 
 
25% for each ligand.
The ability of whole bacteria to inhibit binding between pure
M22 protein and mouse anti-M22 (1–19) was analyzed essentially
as described previously (32). In brief, washed bacteria were used
to inhibit the binding of antibodies (diluted 100-fold) to microti-
ter wells coated with 1 
 
 
 
g/ml M22. After washes, bound mouse
IgG was detected by the addition of rabbit anti–mouse IgG, fol-
lowed by radiolabeled protein G.
 
Phagocytosis Assays.
 
The assays were performed essentially as
described previously (33). Overnight cultures of bacteria in TH
were diluted 1:50 in TH and grown to A
 
620
 
 
 
  
 
0.15 without agi-
tation at 37
 
 
 
C in 5% CO
 
2
 
. After dilution in TH, 25 
 
 
 
l of bacte-
rial suspension, containing 
 
 
 
50 CFU, was mixed with 250 
 
 
 
l of
freshly drawn human blood, using hirudin (final concentration,
140 U/ml; Calbiochem) as anticoagulant (25), and the tubes were
rotated at 37
 
 
 
C for 3 h. Bacterial titers in the inoculum and after
incubation were analyzed by the pour plate method. Because
growth may vary between assays performed on different occasions
and with different blood donors, growth is expressed as a fraction
of that seen with the wild-type control strain. The average in-
crease in titer (“multiplication factor”) for the wild-type strain is
given in the figure legends. The opsonizing effect of rabbit antise-
rum was analyzed by the addition of a 50-
 
 
 
l sample to a phago-
cytosis system, using preimmune rabbit serum as control.
The phagocytosis assays used blood from “nonimmune” hu-
man donors (i.e., blood that allowed growth of the M22-express-
ing strain and, therefore, did not contain opsonizing anti-M22
antibodies). Among several donors tested in preliminary experi-
ments, blood from most donors allowed growth of the M22-
expressing strain, and blood from three such donors was used in
each set of phagocytosis experiments, with similar results for each
donor.
 
Analysis of Complement Deposition on S. pyogenes by Flow Cytom-
etry.
 
Overnight cultures of bacteria in TH were diluted 1:20 in
10 ml TH and grown to A
 
620
 
 
 
  
 
0.4 without agitation at 37
 
 
 
C in
Figure 1. Schematic representation of the M22 protein and characterization of ligand-binding regions by affinity chromatography. (A) The M22 protein
can be divided into an NH2-terminal hypervariable region (dark gray; HVR), a semivariable region (light gray), and a conserved COOH-terminal region
with two C-repeats. The locations of two well-characterized regions binding human C4BP and IgA-Fc, respectively, are indicated. A less well-defined region
binding human IgG-Fc (not depicted) is most likely located on the COOH-terminal side of the IgA-binding region (26, 27). The C4BP- and IgA-binding
regions can be studied as  50-residue synthetic peptides, designated M22-N and Sap22, respectively, for which the amino acid sequences are indicated,
except that the peptides also include a COOH-terminal Cys residue to allow dimerization (15, 29). The positions of a 7-residue deletion in the C4BP-
binding region ( 7) and a 14-residue deletion in the IgA-binding region ( 14) are indicated. CW, streptococcal cell wall. (B) Affinity chromatography
demonstrating that the C4BP- and IgA-binding regions of M22 bind their ligands with high specificity. Whole human plasma was applied to columns
containing the immobilized peptides M22-N or Sap22. A control column contained the M5-N peptide, derived from an M protein that does not bind
C4BP or IgA. Proteins bound to the columns were eluted and analyzed by SDS-PAGE under reducing conditions. The Coomassie-stained gel shows
whole human plasma, reference samples of pure human C4BP and IgA, and eluates from the columns, as indicated. The  70-kD band in the M22-N
eluate was identified as the C4BP  -chain, and the two bands in the Sap22 eluate were identified as the heavy (H) and light (L) chains of IgA.T
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5% CO
 
2
 
. After two washes in 10 ml PBS, 300-
 
 
 
l samples of bac-
terial suspensions (
 
 
 
5 
 
 
 
 10
 
6
 
 bacteria) were mixed with 240 
 
 
 
l
freshly prepared nonimmune human serum and incubated at 37
 
 
 
C
for 30 min. The nonimmune serum was obtained from nonim-
mune human blood, defined as described in 
 
Phagocytosis Assays
 
,
and at least two different sera were used in each analysis, with sim-
ilar results. Activation via the classical pathway was blocked with
10 mM EGTA 
 
 
 
 2.5 mM MgCl
 
2
 
, and activation via the classical
and alternative pathways was blocked with 10 mM EDTA. The
incubated bacteria were washed twice with 1.5 ml PBS and resus-
pended in PBS containing mAb (total volume, 300 
 
 
 
l; mAb con-
centration, 20 
 
 
 
g/ml) at room temperature for 10 min. After
washing with 1.5 ml PBS, the bacteria were resuspended in 300 
 
 
 
l
FITC-conjugated goat F(ab
 
 
 
)
 
2
 
 anti–mouse IgG that had been di-
luted 1:10 in PBS, and incubated for 10 min at room temperature.
Finally, the bacteria were washed with PBS and resuspended in
800 
 
 
 
l PBS for flow cytometry analysis on an Epics II flow cy-
tometer (Coulter Electronics). The instruments forward scatter,
side scatter, and fluorescence 1 were set at 157, 26, and 663 V, re-
spectively, and the forward scatter discriminator was set at 10.
 
Results
Ligand-binding Regions of the M22 Protein. The C4BP-
and IgA-binding regions of M22 can be studied as  50-res-
idue synthetic peptides, which retain ability to bind the
corresponding ligands (15, 27, 29). These ligand-binding
peptides were designated M22-N and Sap22, respectively
(Fig. 1 A). The defined binding regions and the correspond-
ing synthetic peptides have overlapping amino acid se-
quences (27, 29), but the two binding sites in M22 are non-
overlapping (i.e., C4BP does not inhibit binding of IgA,
and vice versa; reference 13). The IgA-binding region binds
serum IgA and secretory IgA of both subclasses (27, 29).
The two peptides specifically bind their ligands in human
serum (15, 29). Because an important aspect of the work re-
ported here involved phagocytosis assays with human
blood, a situation where the bacteria are exposed to whole
plasma, the binding specificity of the two peptides was fur-
ther analyzed under these conditions. Whole human plasma
was applied to columns containing immobilized peptide and
bound proteins were eluted and analyzed by SDS-PAGE
(Fig. 1 B). Anticoagulation was achieved with hirudin, a
specific thrombin inhibitor (34), to avoid possible problems
associated with the use of citrate or EDTA plasma. Protein
eluted from the M22-N column was pure C4BP, with a
major  70 kD band identified as the C4BP  -chain by re-
activity with specific antiserum (15). Material eluted from
the Sap22 column was pure IgA, with major bands identi-
fied as   heavy and light chains, respectively (29). In con-
trast, no plasma protein was retained in a column containing
the control peptide M5-N, derived from an M protein that
does not bind C4BP or IgA (15). Thus, the two M22-
derived peptides specifically bound C4BP and IgA, respec-
tively, among all proteins in whole human plasma, confirm-
ing the high binding specificity of the regions.
Characterization of S. pyogenes Mutants Affected in the Bind-
ing of C4BP and/or IgA. The role of the C4BP- and IgA-
binding regions in phagocytosis resistance was analyzed
with isogenic bacterial mutants, specifically affected in
binding of one or both of the ligands.
A mutant ( 7) specifically lacking the ability to bind
C4BP, due to a seven-residue deletion in the C4BP-bind-
ing region (Fig. 1 A), has been described previously (19).
For studies of the IgA-binding region, we constructed
the  14 strain, which has a 14-residue deletion in the
COOH-terminal part of the IgA-binding region (Fig. 1
A). The  14 and  7 deletions were designed to corre-
spond to 14 and 7 residues, respectively, to leave intact a
possible 7-residue periodicity in the coiled coil M protein
(5). The double mutant  7 14 carried both deletions. To
avoid possible effects of plasmids, the different deletions
were introduced into the streptococcal chromosome by
homologous recombination. To exclude the possibility
that any property of the strains was due to inadvertent in-
troduction of a secondary mutation during strain construc-
tion, a revertant strain (rev.) was constructed, in which the
Figure 2. Effect of short chromosomal deletions in the gene encoding
the M22 protein on the ligand-binding and immunological properties of
S. pyogenes strains. (A and B) Washed suspensions of bacteria were analyzed
for ability to bind radiolabeled C4BP or IgA, as indicated. The two strains
designated  7 and  14 carried the corresponding deletions (Fig. 1 A) and
the  7 14 strain carried both deletions. M22-positive and -negative control
strains were included, as indicated. A third control (rev.) was derived
from the  7 14 strain by reintroduction of the wild-type allele. (C) Sur-
face expression of the M22 protein in the different mutants analyzed with
rat antibodies against the M22 (181–201) peptide, derived from the conserved
C-repeat region. Washed bacteria were incubated with the antiserum, diluted
as indicated, and bound antibodies were identified by incubation with radio-
labeled protein A. Binding for the M22-positive control at the lowest
antiserum dilution was defined as 100%. (D) Immunological characterization
of the most NH2-terminal part of the M22 protein in the different mutant
strains. The binding between mouse antibodies against the M22 (1–19)
peptide and pure M22, immobilized in microtiter wells, was inhibited
with whole bacteria of different strains as indicated. Symbols are explained in
A. The data in A–D are based on three different experiments with duplicate
samples and are presented as means   SD.T
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wild-type emm22 allele was reintroduced into the double
mutant  7 14.
The ability to bind C4BP and IgA was analyzed for the
strain expressing the M22 protein, for its mutant lacking
M22, and for the isogenic mutants described above (Fig.
2, A and B). As expected, the M22-negative strain com-
pletely lacked ability to bind C4BP and IgA. The  14
mutation eliminated binding of IgA, but had little or no
effect on the binding of C4BP, implying that this muta-
tion specifically affected the IgA-binding domain and did
not affect surface expression of M22. Similarly, the  7
mutation abolished binding of C4BP, but not of IgA, in
agreement with previous observations (19). The double
mutant   7 14 completely lacked ability to bind both
ligands, whereas the revertant strain bound C4BP and IgA
equally well as the wild type. These results indicated that
the  14 and  7 mutations specifically affected the ability
to bind C4BP or IgA, respectively, making them suitable
for further analysis.
To analyze whether the different mutations affected the
level at which the M22 protein is expressed on the bacterial
surface, the bacterial mutants were analyzed for ability to
react with antibodies raised against an internal peptide,
M22 (181–201), derived from the conserved C-repeat re-
gion of the M22 protein (Fig. 2 C). These antibodies
showed similar reactivity with all strains except the M22-
negative strain, indicating that the mutant M22 proteins
were expressed normally on the bacterial cell surface. This
conclusion was confirmed by analysis of the ability of the
strains to bind a third M22 ligand, IgG-Fc, which may bind
at a site located between the IgA-binding region and the
conserved C-repeat region (26). All strains except the
M22-negative strain had similar IgG-Fc–binding ability,
confirming that the M22 protein was expressed at normal
levels in the mutants (unpublished data).
The ability of the  7 mutant to bind IgA and of the
 14 mutant to bind C4BP indicated that the global struc-
ture of the NH2-terminal part of the M22 protein was not
distorted in these mutants. However, it could not be ex-
cluded that the combination of the two single mutations in
 7 14 caused a change in structure of the NH2-terminal
region, affecting the ability of M22 to confer phagocytosis
resistance. To analyze this problem, we used mouse anti-
bodies raised against a synthetic peptide derived from the
first 19 residues of M22, a region present in all of the mu-
tants. This region of M22 was of particular interest, be-
cause the most NH2-terminal part of M protein has been
implicated in phagocytosis resistance (5, 9). Binding of the
anti-M22 (1–19) antibodies to pure M22 protein was in-
hibited by bacteria expressing the wild-type M22 protein,
but not by M22-negative bacteria, as expected (Fig. 2 D).
Moreover, binding was inhibited equally well by the three
strains  7,  14, and  7 14. These data indicate that the
structure of the most NH2-terminal region of M22 was
not distorted in any of the mutants, implying that they
were all suitable for analysis of the role of the ligand-bind-
ing regions in phagocytosis resistance.
The C4BP- and IgA-binding Regions of M22 Cooperate in
Conferring Phagocytosis Resistance. The contribution of the
two regions to phagocytosis resistance was analyzed in the
classical bactericidal assay, which measures the ability of
streptococci to grow in whole human blood (33). How-
ever, hirudin rather than heparin was used for anticoagula-
tion, as described previously (25), because heparin may in-
terfere with complement activity.
The growth of the M22-negative control strain in whole
blood was reduced 20-fold compared with the M22-positive
control strain, whereas growth of the  7 and the  14 strains
was reduced 2.6-fold and 2-fold, respectively (Fig. 3). Thus,
a mutation affecting only one of the ligand-binding regions
had a limited but significant effect on phagocytosis resis-
tance. The effect of the  7 mutation was smaller in these ex-
periments than in previously reported tests (19), possibly due
to variability in the whole-blood phagocytosis system.
The growth of the double mutant  7 14 was reduced
to the same level as the M22-negative strain (Fig. 3). Thus,
the ability of the M22 protein to confer phagocytosis resis-
tance may be fully explained as cooperation between the
C4BP- and IgA-binding regions. Moreover, comparison of
the single mutants with the double mutant indicates that
each of the two ligand-binding regions makes an important
contribution to phagocytosis resistance. Importantly, the
revertant strain (rev.) had regained full resistance, demon-
strating that the lack of growth of the  7 14 double mu-
tant was indeed due to the two mutations affecting the
M22 protein. The reduced growth of the mutants in the
phagocytosis system was not due to a general effect on
growth, because all strains grew equally well in human
plasma (unpublished data).
S. pyogenes Activates Complement via the Classical Pathway
but Activation Is Down-regulated by Bacteria-bound C4BP. It
seemed possible that bacteria-bound C4BP contributed to
phagocytosis resistance by down-regulating the deposition
Figure 3. Role of the C4BP- and IgA-binding regions for ability of the
M22 protein to confer phagocytosis resistance. The six strains described in
Fig. 2 were analyzed for ability to grow in whole human blood during a 3-h
period. Anticoagulation was achieved with hirudin. Bacterial growth is
expressed as a ratio of the growth observed for the strain expressing the
wild-type M22 protein, for which the average factor of growth (multiplica-
tion factor) in these experiments was 395. Data are based on eight experi-
ments with three different blood donors and presented as means   SD.T
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of complement (19). In agreement with this hypothesis,
bacteria-bound C4BP was found to retain its cofactor ac-
tivity (13). However, the role of C4BP remained unclear,
because phagocytosis was analyzed with blood from non-
immune donors (i.e., in the absence of opsonizing antibod-
ies; reference 19), when the classical pathway of comple-
ment activation was not expected to be activated. This
situation prompted us to analyze complement deposition
on S. pyogenes under nonimmune conditions, with particu-
lar focus on the role of bacteria-bound C4BP and deposi-
tion via the classical pathway.
Analysis of complement deposition on the surface of S.
pyogenes was performed by flow cytometry, after incubation
of bacteria in nonimmune human serum (Fig. 4).
Figure 4. Analysis of complement deposition on the surface of S. pyogenes. Bacteria were incubated for 30 min in nonimmune human serum and analyzed
by FACS® for bound complement components as indicated. Strains used were S. pyogenes expressing the M22 protein (M22-pos.), its M22-negative mutant
(M22-neg.), and the two mutants  7 and  14. For each type of analysis, results obtained in at least three different experiments are shown to the left as
means   SD, and representative histograms are shown to the right. Data obtained with a subclass control are shown in E. (A) Deposition of C3d on
M22-negative S. pyogenes incubated in normal human serum (NHS), in serum with EDTA, or in serum with Mg-EGTA. Deposition in normal human
serum was defined as 1.00 (left). (B) Deposition of C3d on the M22-positive strain and its mutants. Deposition of C3d on the M22-positive strain was
defined as 1.00. (C) Complement activation via the classical pathway, analyzed with mAbs against C4c and C4d. The C4d/C4c ratio observed for the
M22-negative strain was defined as 1.00. (D) Binding of C4BP, analyzed with the anti-C4BP mAb67. Binding of C4BP to the M22-positive strain was
defined as 1.00. (E) Control with an IgG1 mAb.T
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Complement activation via the classical or alternative
pathways results in surface deposition of C3b and fragments
of C3b, all of which can be identified with an anti-C3d
mAb (16). As expected, C3d was deposited on M22-nega-
tive bacteria incubated in nonimmune serum, and deposi-
tion was abolished by the addition of EDTA, which inhib-
its both pathways (Fig. 4 A). Interestingly, C3d-deposition
was reduced 20-fold also in the presence of Mg-EGTA,
which blocks only the classical pathway. Thus, deposition
of complement on the M-negative strain occurred almost
exclusively via the classical pathway.
Deposition of C3d was approximately threefold higher
on the M22-negative strain than on the M22-positive
strain, implying that expression of the M22 protein inhibits
most of the complement deposition occurring via the clas-
sical pathway (Fig. 4 B). Deposition of C3d on the  7
strain was increased approximately twofold, but this result
was not significantly different from the approximate three-
fold increase seen for the M22-negative strain. Comple-
ment deposition on the  14 strain was only slightly in-
creased, indicating that the IgA-binding region has little or
no effect on complement deposition. These data indicate
that the ability of the M22 protein to inhibit surface depo-
sition of complement under nonimmune conditions may
be entirely due to the ability of M22-bound C4BP to in-
hibit activation via the classical pathway.
Activation of the classical pathway results in surface dep-
osition of C4b, which in the presence of C4BP and factor I
is degraded to C4c and C4d. The C4c part is released into
the medium, whereas C4d remains bound to the surface
(16, 17). Thus, the C4d/C4c ratio will be increased if the
classical pathway is down-regulated by C4BP (35). The
deposition on S. pyogenes of these complement components
was analyzed with specific mAbs. The C4d/C4c ratio was
approximately threefold higher on the M22-positive strain
(Fig. 4 C), implying that the M22 protein inhibited activa-
tion of complement occurring via the classical pathway un-
der nonimmune conditions. The ratio observed for the  7
mutant was only slightly higher than for the M22-negative
control, and the difference was not statistically significant,
indicating that the ability of M22 to down-regulate the
classical pathway was due to its ability to bind C4BP. In
contrast, the  14 mutant was not affected in the ability to
inhibit complement deposition via the classical pathway,
indicating that the IgA-binding region inhibits phagocyto-
sis by a different mechanism. These data support the con-
clusion that the C4BP-binding region of the M22 protein
causes down-regulation of the classical pathway.
To analyze whether the bacterial strains bound C4BP
under the conditions of the FACS® analysis, binding of
C4BP was analyzed with the anti-C4BP mAb67, which is
directed against an epitope in C4BP located outside the M
protein binding site (30). In agreement with the results ob-
tained with radiolabeled C4BP (Fig. 2), binding of C4BP
was reduced  100-fold for the M22-negative strain and for
the  7 mutant, whereas binding to the  14 strain was al-
most unaffected (Fig. 4 D).
Antibodies Directed against the C4BP- and IgA-binding Re-
gions Are Opsonizing. The role of the ligand-binding re-
gions of M22 under immune conditions was analyzed with
specific antisera. Attempts to raise rabbit antisera that spe-
cifically inhibited binding of only one ligand were unsuc-
Figure 5. Ability of polyclonal
antisera, directed against different
parts of M22, to inhibit ligand
binding and opsonize for phago-
cytosis. (A) Localization in the
M22 protein of the three peptides
M22-N, Sap22, and C22 used to
raise rabbit antisera. (B) Reactivity
of antipeptide antisera with pure
M22 protein immobilized in
microtiter wells. Bound Abs
were detected with radiolabeled
protein G. The sera had been
adjusted to have similar titer by
appropriate dilution in preimmune
serum. (C and D) Ability of anti-
peptide antisera to inhibit binding
of radiolabeled C4BP or IgA to
pure M22 protein immobilized
in microtiter wells. Symbols are
explained in B. The data in B–D
are based on three experiments
with duplicate samples and are
presented as means   SD. (E)
Phagocytosis experiments. The
antipeptide antisera were analyzed
for ability to opsonize the M22-
positive strain. As controls, the M22-positive strain and an isogenic M22-negative mutant were analyzed for growth in the presence of preimmune rabbit
serum. Bacterial growth was determined after incubation in whole human blood for 3 h, using hirudin as anticoagulant, and is expressed as a ratio of the
growth observed for the strain expressing the M22 protein, for which the average factor of growth (multiplication factor) in these experiments was 461.
Each analysis is based on at least three separate experiments with three different blood donors and the data are presented as means   SD.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Phagocytosis Resistance in Streptococcus pyogenes 1064
cessful, apparently because antibodies to one region steri-
cally inhibit the binding of both ligands (see the last
paragraph in Results). Therefore, analysis under immune
conditions was performed with sera raised against the two
peptides M22-N and Sap22, of which the anti–M22-N se-
rum has been studied previously (19). The analysis also
used an antiserum raised against a 54-residue peptide desig-
nated C22, derived from the conserved C-repeat region,
which is not believed to influence phagocytosis resistance
(Fig. 5 A; reference 36).
To allow direct comparisons, the three antisera were ap-
propriately diluted in preimmune rabbit serum, resulting in
similar reactivity with the M22 protein (Fig. 5 B). Binding
of C4BP to the M22 protein was inhibited by the anti–
M22-N serum and approximately sixfold less well also by
the anti-Sap22 serum, but not by the anti-C22 serum (Fig.
5 C). In contrast, binding of IgA was inhibited by all three
antisera (Fig. 5 D). The surprising ability of the anti-C22
serum to inhibit binding of IgA was not due to cross-reac-
tivity of the C22 peptide with the IgA-binding region (un-
published data), but was probably due to steric hindrance.
Preimmune rabbit serum caused some inhibition of IgA-
binding, possibly because rabbit IgA competes with human
IgA for binding to M22.
In phagocytosis experiments, each of the anti–M22-N and
anti-Sap22 antisera efficiently opsonized the M22-expressing
strain, reducing growth to the level of the M22-negative
control (Fig. 5 E). In contrast, the anti-C22 antibodies
lacked opsonizing capacity. Thus, antisera that blocked bind-
ing of both C4BP and IgA promoted phagocytosis.
Antibodies Specific for the C4BP- or IgA-binding Region
Inhibit Binding of Both Ligands. Because the M22-N and
Sap22 peptides have overlapping sequences (Fig. 1 A), it
was not surprising that antisera against these peptides inhib-
ited binding of both ligands (Fig. 5). Indeed, each of these
sera reacted not only with the homologous peptide but also
with the heterologous peptide (unpublished data). Antisera
specific for either of the two ligand-binding regions were
prepared by absorption of the anti–M22-N and anti-Sap22
antisera with the heterologous peptide, as described in Ma-
terials and Methods. Such absorptions made the antisera al-
most completely specific for the homologous peptides (Fig.
6, A and B). Nevertheless, these absorbed antisera retained
the ability to inhibit binding of both ligands to the M22
protein (Fig. 6, C and D), most likely due to steric hin-
drance, and they retained the ability to reduce growth in
blood (unpublished data). Thus, polyclonal antibodies spe-
cific for one ligand-binding region blocked binding of both
ligands and promoted phagocytosis.
Discussion
Among pathogenic bacteria, S. pyogenes is unique in its
ability to grow rapidly in nonimmune whole human blood.
This property is to a large extent due to the expression of
surface M protein, which inhibits phagocytosis by neutro-
phils (5). Although S. pyogenes is usually not found in the
blood of infected individuals, but causes infections on mu-
cosal surfaces or in wounded tissue, the ability of M protein
to inhibit phagocytosis is probably an important virulence
mechanism also under these conditions, because phago-
cytes will be recruited to the site of an infection. Interac-
tions between M proteins and human plasma proteins are
also expected to occur on mucosal surfaces, where plasma
exudative responses contribute to a first-line defense system
(37). Indeed, it seems likely that the most important inter-
actions between S. pyogenes and the immune system occur
on mucosal surfaces.
To analyze the molecular mechanisms by which M pro-
tein confers phagocytosis resistance, we used the M22 pro-
tein, in which the HVR binds C4BP and the semivariable
region binds IgA. The very high specificity with which
these regions bind their human ligands strongly suggests
that the interactions are biologically significant. Impor-
tantly, it was possible to construct M22 mutants specifically
affected in binding of only one of the ligands, allowing
analysis of the role of each ligand in phagocytosis resistance.
Moreover, a double mutant had immunological and
ligand-binding properties, indicating that it could be
viewed as the sum of the two single mutants. Characteriza-
tion of these different mutants demonstrated that each
ligand-binding region made a major contribution to
phagocytosis resistance, whereas full resistance required the
Figure 6. Antibodies specific for either of the C4BP- or IgA-binding
regions in M22 inhibit binding of both ligands. (A and B) Antisera against
either of the M22-N and Sap22 peptides were absorbed with the heter-
ologous peptide and analyzed for reactivity with the indicated peptide,
which was immobilized in microtiter wells. (C and D) Ability of the
absorbed sera to inhibit binding of radiolabeled C4BP or IgA to pure
M22 protein immobilized in microtiter wells.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Carlsson et al. 1065
activity of both regions. The mutant lacking ability to bind
both ligands was as sensitive to phagocytosis as an M-nega-
tive strain, implying that phagocytosis resistance conferred
by the M22 protein can be fully explained as cooperation
between the C4BP- and IgA-binding domains. Because
M22 has properties typical of many M proteins, it seems
likely that binding of C4BP and IgA contributes to phago-
cytosis resistance in many strains of S. pyogenes. For exam-
ple, the purified M4, M28, and M60 proteins have binding
properties very similar to those of the M22 protein (13,
38). This situation raises the question of the role of C4BP
and IgA in phagocytosis resistance.
Efficient phagocytosis of a bacterial pathogen under non-
immune conditions requires opsonization by complement
(3), implying that a pathogen may evade phagocytosis by
interfering with complement deposition. Therefore, bind-
ing of C4BP to the surface of S. pyogenes can most simply
be explained as a mechanism that allows evasion of com-
plement attack (13, 19). However, the role of bacteria-
bound C4BP has remained unclear, because this comple-
ment regulator specifically inhibits activation of the classical
pathway, which is commonly believed not to be activated
under nonimmune conditions. The data reported here re-
solve this paradox, because deposition of complement on
the M-negative S. pyogenes strain occurred almost exclu-
sively via the classical pathway even under nonimmune
conditions but was reduced by the C4BP-binding region of
M22. Thus, bacteria-bound C4BP limits classical pathway
activation occurring under nonimmune conditions, a find-
ing that may explain why bound C4BP contributes to the
protection of S. pyogenes against phagocytosis.
The M22 protein reduced total complement deposition
approximately threefold, but not completely. Therefore, it
could be argued that the residual complement deposited on
M22-expressing bacteria might be sufficient to permit
phagocytosis. However, studies of Neisseria gonorrhoeae have
indicated that a fourfold reduction in complement deposi-
tion, as measured in vitro, is sufficient to confer full resis-
tance to complement (39), and a similar situation may pre-
vail in S. pyogenes. Moreover, the inability of M22 to
completely block complement deposition may explain why
two regions in M22 are required to confer full resistance to
phagocytosis.
The conclusion that S. pyogenes activates the classical
pathway is in agreement with accumulating evidence that
this pathway is continuously activated at low levels, even
under nonimmune conditions and may be further activated
by pathogens (40, 41). Indeed, the classical pathway may be
more important than the alternative pathway for clearance
of some infections under nonimmune conditions (41–43).
Among the mechanisms that cause activation of the classical
pathway under nonimmune conditions, particular interest
has been focused on “natural IgM,” which is present in
nonimmune individuals and recognizes pathogens (44–46).
Other mechanisms for activation of the classical pathway
under nonimmune conditions include direct interaction of
bacteria with complement component C1 and activation
of the mannose-binding lectin pathway (47). The latter
mechanism may be of particular relevance to S. pyogenes,
which binds the mannose-binding lectin (48).
The function of the IgA-binding domain in phagocytosis
resistance is less readily explained than that of the C4BP-
binding region. Indeed, it may appear paradoxical that the
ability of S. pyogenes to bind a component of the adaptive
immune system confers phagocytosis resistance under non-
immune conditions. However, the molecular mechanism by
which IgA-binding M proteins interact with IgA throws
light on this problem. The IgA-binding region of different
M proteins binds at the C 2–C 3 interface in the Fc part of
IgA (49), at a site similar to that used by the human IgA re-
ceptor CD89, which is expressed on phagocytes and pro-
motes IgA-mediated phagocytosis (50, 51). Consequently,
an IgA-binding M protein inhibits the binding of IgA-Fc to
CD89, thereby inhibiting IgA effector function (49). With
regard to S. pyogenes infections, a possible scenario is, there-
fore, that IgA-binding M proteins block IgA-mediated
phagocytosis promoted by “natural” IgA antibodies under
nonimmune conditions (49). This hypothesis is supported by
the observation that normal human subjects have natural IgA
antibodies against a large number of S. pyogenes antigens (52).
According to the arguments put forward in the previous
paragraphs, the C4BP- and IgA-binding regions in M22
and similar M proteins allow S. pyogenes to evade opsoniza-
tion by two mechanisms: (a) the C4BP-binding region
down-regulates activation of complement via the classical
pathway and (b) the IgA-binding region may interfere with
IgA-mediated opsonization (Fig. 7). It is noteworthy that
each of the ligand-binding regions must be inactivated to
confer full sensitivity to phagocytosis, implying that both
regions make important contributions to phagocytosis re-
sistance. This observation is in agreement with many re-
Figure 7. Model for the role of human C4BP and IgA in resistance to
phagocytosis conferred by M22 and related M proteins. The two ligands
bind to separate sites in the NH2-terminal part of M22, which is a dimeric
coiled coil. The size and shapes of the molecules are drawn approximately
to scale (references 17, 60–62). The C4BP molecule has seven identical
 -chains and one short  -chain composed of complement control protein
modules. The M protein binds to C4BP at the module 1–2 interface in the
  chain (references 30, 63). The binding site for M protein in IgA is located
at the C 2–C 3 interface in the Fc part (reference 49). According to the
model, bacteria-bound C4BP protects against complement-mediated op-
sonization, which occurs via the classical pathway even under nonimmune
conditions. The ability to bind IgA-Fc may allow the bacteria to interfere
with phagocytosis promoted by natural IgA.T
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ports that efficient phagocytosis of pathogens requires op-
sonization by both complement and immunoglobulin (53).
The studies reported here were focused on the C4BP-
and IgA-binding regions of M22, because these well-char-
acterized regions are located in the variable NH2-terminal
part of M22 and bind their ligands with high specificity.
However, the M22 protein also has a less well-defined
IgG-binding region, most likely located COOH-terminally
of the IgA-binding region (26, 27). Little is yet known
about the properties and function of this IgG-binding re-
gion, but it does not appear to contribute to phagocytosis
resistance in nonimmune human blood, because the double
mutant  7 14, which had lost the ability to bind C4BP
and IgA but still bound IgG, was as sensitive to phagocyto-
sis as a strain lacking the entire M protein.
The model presented in this paper can explain how M22
and similar M proteins confer phagocytosis resistance, but
many M proteins (e.g., the extensively studied M5 and M6
proteins) do not bind C4BP and IgA and must use different
mechanisms to inhibit phagocytosis. Although the plasma
proteins fibrinogen, factor H, and factor H-like protein 1
have been implicated in phagocytosis resistance conferred
by these M proteins (54–56), their role remains unclear.
The complexity of phagocytosis resistance is emphasized by
the finding that the genetic background of a strain influ-
ences M protein function (57, 58). For example, the M22
protein does not confer phagocytosis resistance in the M5
background and vice versa (58). This phenomenon limits
the possibility to use heterologous hosts or hybrid M pro-
teins for analysis of M protein function.
An important aspect of the work reported here is that
phagocytosis resistance was analyzed under both nonim-
mune and immune conditions. Analysis under nonimmune
conditions showed that each of the C4BP- and IgA-bind-
ing regions contributed to phagocytosis resistance. Simi-
larly, analysis under immune conditions demonstrated that
opsonizing antibodies could be raised against either of the
overlapping synthetic peptides derived from the two
ligand-binding regions. The opsonizing ability of these an-
tibodies may be explained by their ability to inhibit bind-
ing of both ligands. Interestingly, the ability to block bind-
ing of both ligands was retained by antibodies made
specific for one region by absorption, indicating that anti-
bodies to one region sterically block binding of both
ligands. This finding implies that sequence changes in one
region may allow escape from opsonizing antibodies di-
rected against that region, which could explain the known
sequence variability in the two ligand-binding regions (14,
23). Together, these data indicate that the two ligand-
binding regions play important roles under both nonim-
mune and immune conditions.
Polyclonal antibodies directed against the C-repeat re-
gion of M22 did not opsonize, in agreement with earlier
papers indicating that the C-repeat region does not con-
tribute to phagocytosis resistance (10, 36). These nonop-
sonizing antibodies directed against the C-repeat region ac-
tually blocked the binding of IgA, probably due to steric
effects, but their lack of opsonizing capacity may be at least
partially explained by their lack of effect on the binding of
C4BP.
In summary, the data reported here indicate that M22
and similar M proteins confer phagocytosis resistance
through cooperation between two variable regions that
bind human C4BP and IgA, respectively, two components
of the humoral immune system. Interestingly, an unrelated
streptococcal surface protein, the   protein of group B
streptococcus, also has separate binding sites for IgA and a
human complement regulator, in that case the plasma pro-
tein factor H (59). Thus, the ability of a bacterial surface
protein to simultaneously interact with human IgA and a
human complement regulator may be a virulence mecha-
nism of general significance. Development of methods to
inhibit these interactions could provide novel approaches
to the therapy and prevention of streptococcal infections.
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